3 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
Follow Bone Cancer: new trials by email Literature Review of Bone Cancer trials Research Report on Bone Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Finding Study to Treat Bone Tumor(s) 153-Sm-DOTMP (Samarium-153-DOTMP) - Bone Cancer, Bone Tumor | Phase 1 | Terminated | QSAM Therapeutics, Inc. | 5 | 2022-04-05 | 2026-07-23 |
| Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. 177Lu-3BP-227 (also called 177Lu-IPN01087) - Pancreatic Ductal Adenocarcinoma, Colorectal Cancer | Phase 1 | Terminated | Ipsen | 14 | 2018-05-03 | 2023-12-12 |
| A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) Temozolomide, Vincristine, Ifosfamide - Neoplasms, Solid Tumors | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 4 | 2009-11-11 | 2018-08-27 |
Bone Neoplasms (3) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neuroblastoma (1) · Recurrence (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
Bone Diseases (3) · Musculoskeletal Diseases (3) · Neoplasms by Site (3) · Carcinoma (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Carcinoma, Squamous Cell (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
Cyclophosphamide (1) · Doxorubicin (1) · Etoposide (1) · Ifosfamide (1) · Irinotecan (1) · Temozolomide (1) · Vincristine (1) · robatumumab (1)
Ipsen (1) · Merck Sharp & Dohme LLC (1) · QSAM Therapeutics, Inc. (1)
United States (2) · Belgium (1) · France (1) · Netherlands (1) · Switzerland (1)
Barry Sugarman (1)
2017 (1)